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Introduction
Resistance of effector T cells (Teff) to suppression con-
tributes to disturbed immune regulation in autoimmune
disease. Targeting this unresponsiveness to suppression
might therefore have beneficial effects in autoimmune
inflammation. In juvenile idiopathic arthritis (JIA) we
have recently shown that Teff from inflamed joints are
refractory to suppression, which was associated with
enhanced PKB/c-akt activation in these cells.
Objectives
To investigate whether anti-IL-6 and anti-TNFa target
unresponsiveness of Teff to suppression in patients with
JIA.
Methods
Resistant Teff from the inflamed joints of JIA patients
were cultured in the presence of etanercept or anti-IL-6
in vitro and PKB/c-akt activation and responsiveness to
suppression was measured. In addition, in vivo effects of
TNFa blockade were investigated using peripheral blood
samples of patient before and after start of etanercept
therapy.
Results
In vitro treatment of synovial fluid Teff with anti-IL-6 led
to improved Treg mediated suppression of cell prolifera-
tion in some, but not all patients. Blocking TNFa with eta-
nercept however clearly enhanced suppression in all
samples analyzed. In the presence of etanercept PKB/c-akt
activation of Teff was reduced and Teff became more
susceptible to TGFb-mediated suppression, indicating that
anti-TNFa directly targets resistant Teff.
Conclusion
This study is the first to show resistance of Teff to sup-
pression as a target of anti-TNFa therapy in arthritis,
resulting in improved regulation of inflammatory effector
cells.
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